Table 2.
Clinical characteristics of CD20-negative diffuse large B-cell lymphoma and CD20-positive diffuse large B-cell lymphoma patients
| Total | CD20-negative DLBCL(n = 21) | CD20-positive DLBCL (n = 63) | P | |
|---|---|---|---|---|
|
Age(years) |
|
|
|
|
| Median (range) |
51.5(9-83) |
53(11-83) |
51(9-71) |
0.955 |
| ≤60 |
56(66.7%) |
14(66.7%) |
42(66.7) |
1 |
|
Sex |
|
|
|
|
| Male |
64(76.2%) |
16(76.2%) |
48(76.2%) |
1 |
| Female |
20(23.8%) |
5(23.8%) |
15(23.8%) |
|
|
PS score |
|
|
|
|
| 0-1 |
75(89.3%) |
18(85.7%) |
57(90.5%) |
0.839 |
| ≥2 |
9(10.7%) |
3(14.3%) |
6(9.5%) |
|
|
Stage |
|
|
|
|
| I-II |
49(58.3%) |
12(57.1%) |
37(58.7%) |
0.898 |
| III-IV |
35(41.7%) |
9(42.9%) |
26(41.3%) |
|
|
LDH |
|
|
|
|
| Normal |
50(59.5%) |
14(66.7%) |
36(57.1%) |
0.441 |
| Elevated |
34(40.5%) |
7(33.3%) |
27(42.9%) |
|
|
Extranodal sites |
|
|
|
|
| 0-1 |
73(86.9%) |
16(76.2%) |
57(90.5%) |
0.191 |
| ≥2 |
11(13.1%) |
5(23.8%) |
6(9.5%) |
|
|
IPI |
|
|
|
|
| 0-1 |
44(52.4%) |
11(52.4%) |
33(52.4%) |
1 |
| 2-3 |
40(47.6%) |
10(47.6%) |
30(47.6%) |
|
|
Bulky disease |
|
|
|
|
| Yes |
20(23.8%) |
8(38.1%) |
12(19%) |
0.076 |
| No |
64(76.2%) |
13(61.9%) |
51(81%) |
|
|
BM involvement |
|
|
|
|
| Yes |
2(2.4%) |
2(9.5%) |
0(0) |
0.06 |
| No |
82(97.6%) |
19(90.5%) |
63(100%) |
|
|
B symptom |
|
|
|
|
| Present |
23(27.4%) |
8(38.1%) |
15(23.8%) |
0.204 |
| Absent |
61(72.6%) |
13(61.9%) |
48(76.2%) |
|
|
First-line chemotherapy |
|
|
|
|
| CHOP or CHOP-like |
79(94%) |
20(95.2%) |
59(93.7%) |
1 |
| Other regimens |
5(6%) |
1(4.8%) |
4(6.3%) |
|
|
Radiotherapy |
|
|
|
|
| Yes |
28(33.3%) |
5(23.8%) |
23(36.5%) |
0.285 |
| No |
56(66.7%) |
16(76.2%) |
40(63.5%) |
|
|
Surgery |
|
|
|
|
| Yes |
11(13.1%) |
5(23.8%) |
6(9.5%) |
0.191 |
| No |
73(86.9%) |
16(76.2%) |
57(90.5%) |
|
|
Autologous SCT |
|
|
|
|
| Yes |
4(4.8%) |
1(4.8%) |
3(4.8%) |
1 |
| No |
80(95.2%) |
20(95.2%) |
60(95.2%) |
|
|
Follow-up (months) |
|
|
|
|
| Median (range) | 41.5(2-121) | 13(3-117) | 47(2-121) |
PS, performance status; LDH, lactate dehydrogenase; IPI, international prognosis index; BM, bone marrow; SCT, stem cell transplantation.